Most significant clinical trials of 2024
Dec 23, 2024 · Most significant clinical trials of 2024. From GLP-1RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read outs of 2024.
GSK ceases HSV vaccine - a chance for Moderna and BioNTech
Sep 25, 2024 · GSK recently announced the discontinuation of its herpes simplex virus (HSV) therapeutic vaccine candidate, GSK3943104, following the failure of a Phase I/II clinical trial to …
IDWeek 2024: Moderna’s norovirus vaccine mRNA-1403 shows …
Oct 21, 2024 · At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomised, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA …
AAN 2024: Myostatin inhibitors on the horizon for the treatment …
Apr 16, 2024 · However, presenters at AAN 2024 and key opinion leaders previously interviewed by leading data and analytics company GlobalData highlighted that while these SMN …
CAR-T landscape set to expand in 2024 - Clinical Trials Arena
Jul 2, 2024 · Insurers and government programmes may be reluctant to cover costly treatments. In August 2017, Kymriah broke ground by becoming the first CAR T-cell therapy in the world to …
Home - Clinical Trials Arena
MSD and Eisai’s LEAP gastroesophageal cancer trial sees mixed success. MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free …
HIV: Three trials to watch in 2024 - Clinical Trials Arena
Dec 18, 2023 · Dr. Myron Cohen, head of the HIV Prevention Trials Network says there are four areas of research which are being investigated in HIV; prevention, cure, treatment and treating …
Madrigal Pharmaceuticals enrols patients in cirrhosis drug trial
Oct 22, 2024 · US-based biopharmaceutical company Madrigal Pharmaceuticals has finished enrolling patients in a trial of Rezdiffra (resmetirom), a drug candidate for compensated non …
Aruna to initiate clinical trial of AB126 for acute ischemic stroke
Jan 17, 2024 · Aruna Bio co-founder and chief scientific officer Steven Stice said: “We are thrilled with this validation from the FDA, which not only positions AB126 as the first exosome to enter …
Lebrikizumab, Tralokinumab and Dupilumab compete in AD space
Oct 8, 2024 · Lebrikizumab, tralokinumab and dupilumab to compete in atopic dermatitis space. The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical …